Abrdn Life Sciences Investors (HQL)
| Market Value | 378.83M |
| Revenue (ttm) | 3.98M |
| Net Income (ttm) | 85.30M |
| Shares Out | 28.06M |
| EPS (ttm) | 3.04 |
| PE Ratio | 4.44 |
| Forward PE | n/a |
| Dividend | $1.86 (13.78%) |
| Ex-Dividend Date | Nov 21, 2024 |
| Volume | 94,492 |
| Open | 13.17 |
| Previous Close | 13.15 |
| Day's Range | 13.16 - 13.54 |
| 52-Week Range | 12.76 - 15.90 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HQL
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap c... [Read more]
News
5 Best CEFs This Month For 8.5% Yield (November 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, ...
5 Best CEFs This Month For 9.5% Yield (October 2024)
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generall...
5 Best CEFs This Month For 9% Plus Yield (September 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, ...
Finding Opportunities In The Closed-End Fund World
Closed-end funds have unique features that make them very attractive investment vehicles for the right asset classes and investors who understand them. Especially for complex and/or less liquid asset ...
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team Update
PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSE:HQH), abrdn Life Sciences Investors (NYSE:HQL), abrdn Healthcare Opportunities Fund (NYSE:THQ), and abrdn World Health...
abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH) Announce a 25% Increase in Distribution Rates and abrdn Healthcare Opportunities Fund (THQ) Announces a 60% Increase in Distribution Rate
PHILADELPHIA, PA / ACCESSWIRE / February 9, 2024 / abrdn Life Sciences Investors (HQL), abrdn Healthcare Investors (HQH), and abrdn Healthcare Opportunities Fund (THQ) (collectively, the "Funds") each...
The Month In Closed-End Funds: December 2023
For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV,...
abrdn Announces Its Appointment to Four U.S. Specialist Healthcare Closed-End Funds, New Board of Trustees to the Funds and Fund Name Changes
PHILADELPHIA, PA / ACCESSWIRE / October 27, 2023 / Effective close of business today, October 27, 2023, abrdn Inc. ("abrdn") assumed responsibility for the management of the four (4) former Tekla Capi...
Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc.
BOSTON--(BUSINESS WIRE)--Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its...
Tekla Capital Management LLC Announces Closing of Transaction With abrdn
Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manag...
Tekla Life Sciences Investors Paid Distribution
BOSTON--(BUSINESS WIRE)--On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long...
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth ...
Tekla Funds Announce Second Adjournment of Special Meetings and Urge Shareholder Participation to Limit the Need for Further Solicitation Efforts
BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today ann...
Tekla Life Sciences Investors Declares Distribution
BOSTON--(BUSINESS WIRE)--On August 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is August 25, 2023 and the payable date is S...
Tekla Funds Announce Adjournment of Special Meetings
BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today ann...
HQL: 13% Discount Creates An Opportunity
Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals.
HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield
HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.
Equity CEFs: Top Picks For 2023
2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve t...
5 Best CEFs To Buy This Month (December 2022)
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are g...
Equity CEFs: What's Going On With Tekla's HQH And HQL?
The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biote...
Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.
HQL: A Biotechnology Equity CEF With No Leverage
Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while it...
HQL: Buy For The Yield, If You Can Stomach The Depreciation
HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is impressive. In the past three months, a dividend ...
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
BOSTON--(BUSINESS WIRE)--Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase progra...